Minerva Neurosciences | NERV - Trade Creditors


Minerva Neurosciences reported $640K in Trade Creditors for its fiscal quarter ending in December of 2025.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 10.9M 10.84M Dec/2025
Adma Biologics USD 22.52M 1.5M Dec/2025
ALKERMES USD 107.95M 39.95M Dec/2025
Alterity Therapeutics Limited AUD 1.27M 1.81M Dec/2024
AstraZeneca USD 25.28B 252M Dec/2025
BioCryst Pharmaceuticals USD 15.83M 10.26M Dec/2025
Bristol-Myers Squibb USD 4.29B 1.14B Sep/2025
Cipla INR 30.35B 1.98B Sep/2025
Clal Biotechnology ILS 21.05M 1.62M Dec/2021
Compugen USD 2.35M 6.77M Dec/2025
CSL USD 3.17B 290M Dec/2025
Eli Lilly USD 5.38B 1.12B Dec/2025
Esperion Therapeutics USD 65.07M 12.44M Dec/2025
GlaxoSmithKline GBP 15.38B 294M Dec/2025
Grifols EUR 987.75M 47.87M Dec/2025
Halozyme Therapeutics USD 20.9M 5.54M Dec/2025
Ionis Pharmaceuticals USD 14.33M 8.47M Sep/2025
J&J USD 11.99B 2.37B Dec/2025
Merck USD 4.15B 102M Sep/2025
Minerva Neurosciences USD 640K 305K Dec/2025
Neurocrine Biosciences USD 545.5M 425.6M Dec/2025
Novartis USD 4.46B 99M Dec/2025
Novavax USD 24.58M 9.35M Dec/2025
Pfizer USD 5.02B 142M Sep/2025
Roche Holding CHF 5.78B 1.27B Dec/2025
Sanofi EUR 22.93B 927M Dec/2025
Takeda JPY 467.59B 28.61B Dec/2025
Vanda Pharmaceuticals USD 39.09M 33.28M Dec/2024